NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT04162210: Phase 3 - Belantamab Mafodotin Vs Pomalidomide + Low-dose Dexamethasone (Pom/Dex) RRMM
NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2
NCT03277105: Phase 3 - Subcutaneous vs Intravenous daratumumab in relapsed MM - COLUMBA study
NCT03180736 : Phase 3 - EMN 14 - Pomalidomide and Dexa +/- Dara in relapsed MM - APOLLO study
NCT03151811: Phase 3- Melphalan Flufenamide (Melflufen)-Dex or Pom-dex for RRMM ref. to Len. (OCEAN)
NCT03319667: Phase 3 - Isatuximab, Bortezomib, Lenalidomide and Dexamethasone NDMM (IMROZ)
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM